Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTATOC in Somatostatin Receptor Positive Tumors
NCT03273712Phase 2Completed
- Sponsor
- University of Iowa
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of yttrium-90 edotreotide in Neuroendocrine Neoplasm (NEN), meningioma, neuroblastoma and 1 more, sponsored by University of Iowa. Started Sep 2017; status: completed.
02
Drugs
yttrium-90 edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)meningiomaneuroblastomamedulloblastoma
Beyond the preview
Go deeper on NCT03273712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273712.